Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
N. Thatcher, Fred R. Hirsch, Alexander Valerievich Luft et al. · The Lancet Oncology · 2015
Cited by 479 works. doi:10.1016/s1470-2045(15)00021-2
Authors
- N. Thatcher
- Fred R. Hirsch
- Alexander Valerievich Luft
- Aleksandra Szczęsna
- Tudor–Eliade Ciuleanu
- Mircea Dediu
- Rodryg Ramlau
- Rinat Galiulin
- Beatrix Bálint
- György Losonczy
- Andrzej Każarnowicz
- Keunchil Park
- Christian Schumann
- Martin Reck
- Henrik Depenbrock
- Shivani Nanda
- Anamarija Kruljac‐Letunic
- Raffael Kurek
- Luis G Paz-Ares
- Mark A. Socinski
References
- Nonparametric Estimation from Incomplete Observations
- Nonparametric Estimation from Incomplete Observations
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- AJCC Cancer Staging Manual
- A Sharper Bonferroni Procedure for Multiple Tests of Significance
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
- The Asymptotic Properties of Nonparametric Tests for Comparing Survival Distributions
- AJCC Cancer Staging Manual
- Epidermal Growth Factor Receptor in Non–Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis